18F-Florbetaben PET beta-amyloid binding expressed in Centiloids

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 12, 2017, Pages 2053-2059

  Rowe, Christopher C ^a,b   Doré, Vincent ^a,c   Jones, Gareth ^a   Baxendale, David ^a   Mulligan, Rachel S ^a   Bullich, Santiago ^d   Stephens, Andrew W ^d   De Santi, Susan ^d   Masters, Colin L ^e   Dinkelborg, Ludger ^d   Villemagne, Victor L ^a,b,e  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSIRO   (Australia)

^d Piramal Enterprises Limited   (India)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Alzheimer s disease; Amyloid imaging; Centiloid; Florbetaben; Standardization

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; STILBENE DERIVATIVE;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CENTILOID METHOD; CEREBELLUM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MATHEMATICAL ANALYSIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; YOUNG ADULT; CASE CONTROL STUDY; FEMALE; IMAGE PROCESSING; MALE; METABOLISM; PROCEDURES;

ADULT; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; STILBENES;

EID: 85021141119     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-017-3749-6     Document Type: Article

References (28)

1. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40. doi:10.2967/jnumed.110.076315.
2. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78. doi:10.1016/S1474-4422(12)70142-4.
3. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35. doi:10.1016/S1474-4422(08)70001-2.
4. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25. doi:10.1212/01.wnl.0000261919.22630.ea.
5. Thurfjell L, Lundqvist R, Buckley C, Smith A, Sherwin P. Automated quantification of [18F]flutemetamol data - comparison with standard of truth based on histopathology. J Nucl Med. 2013;54 Suppl 2:302.
6. Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54:723–31. doi:10.2967/jnumed.112.107185.
7. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70–7. doi:10.2967/jnumed.112.109009.
8. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.
9. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.
10. Mourik JE, Lubberink M, Schuitemaker A, Tolboom N, van Berckel BN, Lammertsma AA, et al. Image-derived input functions for PET brain studies. Eur J Nucl Med Mol Imaging. 2009;36:463–71.
11. Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2009;36:1629–38. doi:10.1007/s00259-009-1129-6.
12. Zwan MD, Ossenkoppele R, Tolboom N, Beunders AJ, Kloet RW, Adriaanse SM, et al. Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. J Nucl Med. 2014;55:1305–7. doi:10.2967/jnumed.114.139121.
13. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.
14. Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050–68. doi:10.1016/j.jalz.2014.09.004.
15. Villemagne VL, O’Keefe G, Mulligan RS, Rowe CC. Quantitative approaches to amyloid imaging. Methods Mol Biol. 2011;680:201–25. doi:10.1007/978-1-60761-901-7_14.
16. Yaqub M, Boellaard R, van Berckel BN, Tolboom N, Luurtsema G, Dijkstra AA, et al. Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. Mol Imaging Biol. 2009;11:322–33. doi:10.1007/s11307-009-0208-1.
17. Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O’Meara T, et al. Research and standardization in Alzheimer’s trials: reaching international consensus. Alzheimers Dement. 2013;9:160–8. doi:10.1016/j.jalz.2012.10.006.
18. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1–1-15.e4. doi:10.1016/j.jalz.2014.07.003.
19. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.
20. Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain beta-amyloid load approaches a plateau. Neurology. 2013;80:890–6. doi:10.1212/WNL.0b013e3182840bbe.
21. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem. 2005;48:5980–8. doi:10.1021/jm050166g.
22. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9. doi:10.1007/s00259-012-2088-x.
23. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35. doi:10.1016/S1474-4422(11)70077-1.
24. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7. doi:10.2967/jnumed.111.089730.
25. Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chetelat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4. doi:10.1186/alzrt158.
26. Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86:431–6. doi:10.1136/jnnp-2014-308094.
27. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964–74. doi:10.1016/j.jalz.2015.02.004.
28. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398–407. doi:10.1007/s00259-014-2753-3.